Ligand validation:9F9H

LI1: 1-[2,6,10.14-TETRAMETHYL-HEXADECAN-16-YL]-2-[2,10,14-TRIMETHYLHEXADECAN-16-YL]GLYCEROL

	Best-fitted instance in this entry
	Other instances in this entry

	Best-fitted instance in this entry
	Best-fitted PDB instances with same target (top 5)

	Best-fitted instance in this entry
	Best-fitted PDB instances with different target (top 5)

Identifier	Ranking for goodness of fit	Ranking for geometry	Real space R factor	Real space correlation coefficient	RMSZ-bond-length	RMSZ-bond-angle	Outliers of bond length	Outliers of bond angle	Atomic clashes	Stereochemical errors	Model completeness	Average occupancy
9F9H_LI1_A_304	8%	92%	0.134	0.726	0.27	0.27	-	-	0	0	29%	1
9F9H_LI1_A_303	6%	83%	0.158	0.724	0.42	0.37	-	-	0	0	27%	1
9F9H_LI1_A_310	6%	91%	0.137	0.7	0.27	0.3	-	-	1	0	22%	1
9F9H_LI1_A_301	6%	90%	0.15	0.695	0.2	0.39	-	-	1	0	31%	1
9F9H_LI1_A_316	5%	92%	0.139	0.679	0.36	0.19	-	-	2	0	27%	1
9F9H_LI1_A_302	4%	93%	0.163	0.684	0.33	0.16	-	-	0	0	18%	1
9F9H_LI1_A_311	3%	94%	0.184	0.653	0.33	0.13	-	-	1	0	29%	1
9F9H_LI1_A_312	3%	95%	0.154	0.634	0.24	0.15	-	-	0	0	18%	1
9F9H_LI1_A_315	3%	91%	0.148	0.63	0.32	0.27	-	-	0	0	13%	1
9F9H_LI1_A_313	3%	93%	0.16	0.6	0.29	0.21	-	-	4	0	29%	1
9F9H_LI1_A_314	2%	91%	0.143	0.558	0.31	0.25	-	-	0	0	29%	1
9F9H_LI1_A_305	2%	93%	0.193	0.609	0.26	0.21	-	-	0	0	29%	1
9F9J_LI1_A_301	70%	91%	0.038	0.979	0.16	0.39	-	-	0	0	31%	1
3T45_LI1_B_604	36%	62%	0.142	0.852	0.6	0.85	-	1	11	0	89%	1
2I20_LI1_A_613	34%	60%	0.121	0.929	0.48	1.04	-	1	2	1	29%	1
9F9I_LI1_A_316	31%	91%	0.075	0.897	0.31	0.25	-	-	0	0	13%	1
9F9D_LI1_A_305	29%	61%	0.08	0.861	0.7	0.79	-	-	0	0	29%	1
6G7I_LI1_A_305	27%	63%	0.09	0.884	0.72	0.68	-	-	1	0	18%	1

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.